Table 1.
Personal and clinical characteristics of 70 asymptomatic COVID-19 infected patients in Hunan province, China
| All asymptomatic patients no. (%), (N=70) | Remain asymptomatic no. (%), (N=48) |
Symptom onset no. (%), (N=22) | P value | |
|---|---|---|---|---|
| Age mean (years) | 33.24±20.40 | 29.74±18.92 | 40.86±21.85 | 0.034 |
| Gender | 1 | |||
| Male | 36 (51.4) | 25 (52.1) | 11 (50.0) | |
| Female | 34 (48.6) | 23 (47.9) | 11 (50.0) | |
| Coexisting conditions | ||||
| Hypertension | 6 (8.6) | 3 (6.3) | 3 (13.6) | 0.37 |
| Diabetes | 5 (7.1) | 3 (6.3) | 2 (9.1) | 0.646 |
| Pulmonary disease | 3 (4.3) | 1 (2.1) | 2 (9.1) | 0.231 |
| Drinking history | 3 (4.3) | 0 | 3 (13.6) | 0.028 |
| Smoking history | 11 (15.7) | 4 (8.3) | 7 (31.8) | 0.029 |
| Initial symptoms during quarantine | ||||
| Fever | 4 (5.7) | 4 (18.2) | ||
| Cough | 13 (18.6) | 13 (59.1) | ||
| Chest distress | 2 (2.9) | 2 (9.1) | ||
| Fatigue | 1 (1.4) | 1 (4.5) | ||
| Muscle pain | 0 | 0 | ||
| Pharyngalgia | 1 (1.4) | 1 (4.5) | ||
| Cough and pharyngalgia | 1 (1.4) | 1 (4.5) | ||
| Time interval from RT-PCT positive to symptom onset mean (days) | 4.41±3.55 | |||
| Chest CT scan abnormal | 35 (50.7) | 19 (40.4) | 16 (72.7) | 0.019 |
| Ground-glass shadow | 28 (40.0) | 14 (29.2) | 12 (54.5) | |
| Interstitial abnormalities | 3 (4,.3) | 2 (4.2) | 1 (4.5) | |
| Local patchy shadowing | 2 (2.9) | 1 (2.1) | 1 (4.5) | |
| Subpleural shadowing | 2 (2.9) | 0 | 2 (18.2) | |
| Time from positive chest CT scan to RT-PCR tests mean (days) | 2.91±3.35 | 2.74±3.84 | 3.13±2.75 | 0.732 |
| Time from positive to negative tests with RT-PCR mean (days, range) | 13.20±6.84 (3-34) | 12.46±6.23 (3-32) | 14.82±7.94 (5-34) | 0.18 |
| Leucocytes count mean (× 109/L) | 6.09±1.79 | 6.20±1.96 | 5.84±1.32 | 0.435 |
| Increased (>9.5) | 4 (5.7) | 4 (8.3) | 0 | |
| Normal range (3.5-9.5) | 62 (88.6) | 41 (85.4) | 21 (95.5) | |
| Decreased (<3.5) | 4 (5.7) | 3 (6.3) | 1 (4.5) | |
| Lymphocytes count mean (× 109/L) | 2.66±5.97 | 2.06±1.02 | 3.96±10.59 | 0.216 |
| Increased (>3.2) | 6 (8.6) | 5 (10.4) | 1 (4.5) | |
| Normal range (1.1-3.2) | 56 (80.0) | 38 (79.2) | 18 (81.8) | |
| Decreased (<1.1) | 8 (11.4) | 5 (10.4) | 3 (13.6) | |
| Epidemiology | ||||
| Familial cluster | 5 (7.1) | 4 (8.3) | 1 (4.5) | |
| Close contact history | 3 (4.3) | 3 (6.3) | 0 | |
| Exposure history | 62 (88.6) | 41 (85.4) | 21 (95.5) | |
| Treatment | ||||
| Interferon atomization | 6 (8.6) | 2 (4.2) | 4 (18.2) | |
| Interferon atomization + Arbidol hydrochloride | 5 (7.1) | 4 (8.3) | 1 (4.5) | |
| Interferon atomization + Oseltamivir | 1 (1.4) | 1 (2.1) | 0 | |
| Interferon atomization + Ribavirin | 1 (1.4) | 1 (2.1) | 0 | |
| Interferon atomization + Lopinavi | 33 (47.1) | 22 (45.8) | 11 (50) | |
| Interferon atomization + Lopinavir + Arbidol hydrochloride | 8 (11.4) | 4 (8.3) | 4 (18.2) | |
| Interferon atomization + Lopinavir + Ribavirin | 13 (18.6) | 12 (25) | 1 (4.5) | |
| Lopinavi | 2 (2.9) | 1 (2.1) | 1 (4.5) | |
| Lopinavir + Arbidol hydrochloride | 1 (1.4) | 1 (2.1) | 0 | |
| Clinical outcome | ||||
| Discharged | 70 (100) | 48 (100) | 22 (100) |
Note: All values are expressed as the mean ± standard deviation or number (%) as appropriate according to the primary studies.